Precancerous — Abnormal cells that may turn cancerous

In cellular pathology, precancerous changes—also known as premalignant lesions, dysplasia, or intraepithelial neoplasia—represent an intermediate state between normal tissue and invasive malignancy. Under microscopic examination, precancerous cells exhibit morphological abnormalities, such as enlarged nuclei, disordered architecture, atypical maturation, and increased rates of cell division. However, unlike true cancer cells, precancerous cells remain confined within their original tissue layer and have not breached the basement membrane or invaded surrounding structures.

Precancerous lesions are commonly graded along a continuum from low-grade (mild dysplasia) to high-grade (severe dysplasia or carcinoma in situ), reflecting their likelihood of malignant transformation. While many low-grade lesions regress spontaneously or remain static, high-grade changes harbour genetic alterations that significantly heighten the probability of progression. Recognising and categorising these lesions allows clinicians to tailor preventive management, balancing active surveillance against curative local excision.

Identifying a precancerous condition is one of the most powerful opportunities in modern medicine because it shifts the clinical objective from treating established disease to cancer prevention. At this stage, interventions are typically minor, highly effective, and curative, avoiding the need for aggressive treatments like chemotherapy or radical surgery. Understanding your precancerous diagnosis helps you make informed choices about lifestyle adjustments, adhering to surveillance schedules, and selecting targeted preventive treatments, ultimately stopping invasive cancer before it can threaten your health.

Precancerous lesions are detected through population screening programmes, visual inspection, and tissue sampling. Routine tests include Pap smears and high-risk HPV testing for the cervix, colonoscopy with polyp biopsy for the bowel, mammography for breast calcifications, and upper endoscopy for Barrett's oesophagus. Definitive diagnosis requires histological examination of a tissue biopsy by a pathologist, who evaluates nuclear atypia, tissue architecture, and molecular biomarkers such as p16, Ki-67, or specific genetic mutations to grade the abnormality.

Precancerous lesions occur in many anatomical sites. Key examples include cervical intraepithelial neoplasia (CIN) preceding cervical cancer, adenomatous polyps preceding colorectal cancer, and actinic keratosis preceding squamous cell skin carcinoma. Other common examples include ductal carcinoma in situ (DCIS) in breast tissue, Barrett's oesophagus leading to oesophageal adenocarcinoma, oral leukoplakia preceding head and neck cancer, and monoclonal gammopathy of undetermined significance (MGUS) preceding multiple myeloma.

Management depends on lesion grade, anatomical location, and progression risk. Low-grade abnormalities may be managed with watchful waiting and serial repeat screening. Higher-grade lesions typically warrant active eradication, such as colonoscopic polypectomy, loop electrosurgical excision procedure (LEEP) for cervical dysplasia, cryotherapy or topical 5-fluorouracil for actinic keratoses, or surgical lumpectomy for ductal carcinoma in situ. These minimally invasive procedures eliminate the risk of malignant progression while preserving organ function.